Article
Plerixafor Engages β-Arrestin–Dependent CXCR4 Signaling to Promote Melanogenesis via β-Catenin–MITF Activation
2026-06-02
Abstract excerpt
Plerixafor is a clinically approved CXCR4 antagonist that mobilizes hematopoietic stem cells by disrupting CXCL12/CXCR4 retention signaling. However, its biochemical effects on melanocytes and pigmentation remain unexplored. We investigated how plerixafor modulates CXCR4 sig-naling in melanocytes and evaluated its potential as a pro-melanogenic agent using in vitro and in vivo approaches. Human PIG1 melanocytes we...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ebb21f3e-a5cf-529e-aa8d-e1d9b51a420c
- DOI
- 10.20944/preprints202603.1777.v2
